P/E ratio for Tonix Pharmaceuticals (TNXP)
P/E ratio as of April 2024 (TTM): -0.0122
According to Tonix Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0122321. At the end of 2022 the company had a P/E ratio of -0.0955.
P/E ratio history for Tonix Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0955 | -93.09% |
| 2021 | -1.38 | 60.67% |
| 2020 | -0.8608 | 2160.78% |
| 2019 | -0.0381 | -58.2% |
| 2018 | -0.0911 | -91.23% |
| 2017 | -1.04 | 250.66% |
| 2016 | -0.2962 | -89.36% |
| 2015 | -2.78 | 27.53% |
| 2014 | -2.18 | -29.59% |
| 2013 | -3.10 | 57.16% |
| 2012 | -1.97 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Aerie Pharmaceuticals AERI | -20.3 | 166,129.02% | 🇺🇸 USA |
 Eagle Pharmaceuticals
EGRX | 4.51 | -36,977.31% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.